Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05181826 · ClinicalTrials.gov registry record
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
A clinical trial, sponsored by Helio Genomics.
- Recruiting
- Registry status
- 1,200
- Enrollment target
NCT05181826 is a clinical trial that is actively recruiting participants, run by Helio Genomics. The registered enrollment target is 1,200 participants.
The verdict
NCT05181826 is actively recruiting participants, sponsored by Helio Genomics.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
Study Summary
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Interventions
- DIAGNOSTIC_TEST Multi-analyte Blood Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2028-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05181826
The ClinicalTrials.gov registry entry for NCT05181826 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helio Genomics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multi-analyte Blood Test is the first listed.
NCT05181826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05181826 about?
NCT05181826 is a clinical study titled "Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer". To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) ...
What is the current status of trial NCT05181826?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2019-05-21. Estimated completion is 2028-01.
What interventions are being tested in trial NCT05181826?
The interventions under investigation include: Multi-analyte Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05181826?
This trial is sponsored by Helio Genomics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.